Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/ CBFB::MYH11
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14192 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Juehua Gao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Chromosome Inversion, Chromosomes, Human, Pair 16. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This study assesses the clinical significance of additional cytogenetic abnormalities (ACAs) and/or the deletion of 3′ CBFB (3′ CBFB del ) resulting in unbalanced CBFB::MYH11 fusion in acute myeloid leukemia (AML) with inv (16)/t(16;16)/ CBFB::MYH11 .
Methods
We retrospectively evaluated the clinicopathologic features of 47 adult de novo AML with inv (16)/t(16;16)/ CBFB::MYH11 fusion. There were 44 balanced and 3 unbalanced CBFB::MYH11 fusions. Given the low frequency of unbalanced cases, the latter group was combined with 19 published cases ( N = 22) for statistic and meta‐analysis.
Results
Both balanced and unbalanced cases were characterized by frequent ACAs (56.5% and 72.7%, respectively), with +8, +22, and del(7q) as the most frequent abnormalities. The unbalanced group tends to be younger individuals ( p = .04) and is associated with a lower remission rate ( p = .02), although the median overall survival (OS) was not statistically different ( p = .2868). In the balanced group, “ACA” subgroup had higher mortality ( p = .013) and shorter OS ( p = .011), and patients with relapsed disease had a significantly shorter OS ( p = .0011). Cox multivariate regression analysis confirmed that ACAs and history of disease relapse are independent risk factors, irrespective of disease relapse status. In the combined cohort, cases with ACAs had shorter OS than those with “Sole” abnormality ( p = .0109).
Conclusions
ACAs are independent high‐risk factors in adult AML with inv (16)/t(16;16)/ CBFB::MYH11 fusion and should be integrated for risk stratification in this disease. Larger studies are needed to assess the clinical significance of the unbalanced CBFB::MYH11 fusion resulting from the 3′ CBFB del .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Internal Medicine, Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
ORCID-Profile: Lucy Fu, Qing Chen, Kristy Wolniak, Peng Ji, Madina Sukhanova, Jessica K Altman, Xinyan Lu
Zitieren
APA
Gao, J., Santana-Santos, L., Fu, L., Alvey, E., Chen, Q., Wolniak, K., Xia, Z., Aqil, B., Behdad, A., Ji, P., Sukhanova, M., Abaza, Y., Altman, J. K., Chen, Y. H., & Lu, X. (2024). Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/ CBFB::MYH11. European Journal of Haematology. https://doi.org/10.1111/ejh.14192
Vancouver
Gao J, Santana-Santos L, Fu L, Alvey E, Chen Q, Wolniak K, et al. Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/ CBFB::MYH11. European Journal of Haematology. 2024. doi:10.1111/ejh.14192
BibTeX
@article{Gao2024,
author = {Gao, Juehua and Santana-Santos, Lucas and Fu, Lucy and Alvey, Emily and Chen, Qing and Wolniak, Kristy and Xia, Zongjun and Aqil, Barina and Behdad, Amir and Ji, Peng and Sukhanova, Madina and Abaza, Yasmin and Altman, Jessica K and Chen, Yi-Hua and Lu, Xinyan},
title = {Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/ CBFB::MYH11},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14192}
}
EUVIMED